Skip to main content

Fenofibrate and diabetic retinopathy: an updated systematic review and meta-analysis of randomized controlled trials

In brief

Fenofibrate lowers diabetic retinopathy progression or treatment odds by one-third

Across three randomized trials involving 3,756 people with diabetes, fenofibrate lowered the odds of retinopathy progression or needing retinal treatment by about one-third over up to five years. It also reduced macular edema and laser treatment, but did not reduce moderate vision loss; whether benefits differ by diabetes type or existing retinopathy remains unclear.

Journal
Diabetes research and clinical practice (Q1)
Published
14 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Edhem Dogru, Matheus Pedrotti Chavez, Otávio Toth, Dalyl Nasserdine, Cibele Colembergue da Cunha Burnato, Luke Nicholson
PMID
43034021
DOI
10.1016/j.diabres.2026.113669

Why clinicians should know about it

  • Picked for Ophthalmology (paper of the day, 16 November 2026): Randomized-trial synthesis on fenofibrate and diabetic retinopathy

Abstract

AIMS: To assess fenofibrate effects on diabetic retinopathy (DR) progression and need for retinal treatment. METHODS: PubMed, Embase, and Scopus were searched through June 9, 2026, for randomized trials comparing oral fenofibrate with placebo in adults with type 1 or type 2 diabetes and at least two years of follow-up. The primary outcome was a composite of DR progression or need for retinal treatment. Odds ratios (OR) were pooled using random-effects models. RESULTS: Four trials (20,655 participants) were included; three (3,756) contributed to the primary outcome. Fenofibrate reduced the composite outcome (OR 0.67, 95% CI 0.56-0.81; I2 = 0%), incident macular edema (0.47, 0.29-0.76; I2 = 0%) and need for retinal laser (0.75, 0.65-0.87; I2 = 7%). DR progression on imaging was reduced (0.72, 0.58-0.89; I2 = 0%), but not when FIELD one-step progression was used (0.80, 0.60-1.07). Moderate vision loss (0.99, 0.83-1.18; I2 = 0%) and all-cause mortality (1.01, 0.87-1.17; I2 = 26%) did not differ. Subgroup analyses by diabetes type and baseline retinopathy were underpowered. CONCLUSIONS: Fenofibrate reduces the composite of DR progression or need for retinal treatment over up to five years of follow-up, without a demonstrated effect on moderate vision loss.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.